Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P13637
UPID:
AT1A3_HUMAN
Alternative names:
Na(+)/K(+) ATPase alpha(III) subunit; Sodium pump subunit alpha-3
Alternative UPACC:
P13637; B7Z2T0; B7Z401; F5H6J6; Q16732; Q16735; Q969K5
Background:
Sodium/potassium-transporting ATPase subunit alpha-3, also known as Na(+)/K(+) ATPase alpha(III) subunit or Sodium pump subunit alpha-3, plays a pivotal role in maintaining the electrochemical gradient of sodium and potassium ions across the plasma membrane. This gradient is essential for various cellular processes, including nutrient transport.
Therapeutic significance:
The protein is implicated in several neurological disorders, such as Dystonia 12, Alternating hemiplegia of childhood 2, Cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss, and Developmental and epileptic encephalopathy 99. These associations highlight its potential as a target for therapeutic intervention in these conditions.